Sign in
Taking peoplePhase 2/3

A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD

Key facts

Who runs it
Otsuka Pharmaceutical Co., Ltd.
Where
Japan1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 2/3
People taking part
315 people, planned
Started
3 Sept 2025
Expected to end
Aug 2027
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • EB-1020 (Centanafadine) low dose
  • EB-1020 (Centanafadine) high dose
  • Placebo
Record updated
23 December 2025

Who can take part

Age
6 years to 17 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Participants with a primary diagnosis of ADHD based on DSM-5 diagnostic criteria, differentiated from other mental disorders using the MINI-KID, excluding other specified ADHD or unspecified ADHD
  • Participants with a symptom total raw score of>=28 (if not receiving any pharmacological treatment for ADHD) or>=22 (if receiving pharmacological treatment for ADHD) on the ADHD Rating Scale Version 5 (ADHD-RS-5) at screening
  • Participants with a symptom total raw score of>=28 on the ADHD-RS-5 at baseline
  • Participants with a score of 4 or higher on the Clinical Global Impression Severity - ADHD (CGI-S-ADHD) at baseline

Who cannot take part

  • Participants with a diagnosis of major depressive disorder (MDD), based on the DSM-5 diagnostic criteria who currently have a major depressive episode, or who have required treatment for MDD within the past 3 months prior to screening; Also, participants who, in the judgment of the investigator or subinvestigator, may have a worsening of MDD during the trial or may require treatment during the trial period
  • Participants who cannot agree to discontinuation of prohibited concomitant medication, such as ADHD medication or antidepressants
  • Participants determined to have the following diseases based on an interview using the MINI-KID; Tourette's disorder; Panic disorder; Conduct disorder; Psychotic disorder; Post-traumatic stress disorder; Bipolar disorder
  • Participants with a generalized anxiety disorder requiring pharmacotherapy, based on the DSM-5 diagnostic criteria
  • Participants with an autism spectrum disorder based on the DSM-5 diagnostic criteria
  • Participants with a personality disorder, oppositional defiant disorder, or obsessive-compulsive disorder that is the primary focus of treatment, based on the DSM-5 diagnostic criteria
  • Participants who have a significant risk of committing suicide in the opinion of the investigator or subinvestigator, or based on the following evidence; Active suicidal ideation as evidenced by an answer of "yes" on Questions 4 or 5 (over the last 6 months) on the section of suicidal ideation or a history of suicidal behavior (over the last 6 months) on the Baseline/Screening version of the Columbia-Suicide Severity Rating Scale (C-SSRS) at screening
  • Participants with a diagnosis of substance use disorder; Platelets <= 130,000/mm3; Hemoglobin <= 11.2 g/dL; Neutrophils, absolute <= 1000/mm3; AST > 2 x ULN; ALT > 2 x ULN; eGFR < 45 mL/min/1.73 m2, calculated by the CKiD U25 equation; CPK >= 2 x ULN (except for the cases that the medical monitor determined that participant's inclusion is possible based on the discussion about the participant's condition with the investigator or subinvestigator); Abnormal values for both free T4 and TSH
  • Participants who have a positive pregnancy test result at baseline
  • Participants who have a diagnosis of intellectual disability with an intelligence quotient (IQ) score less than 70

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 6 and 17 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the efficacy and examine the safety of two doses of EB-1020 QD XR capsule administered once daily orally in pediatric ADHD patients.

The 3 groups in the trial

  • EB-1020(QD XR capsules) low doseTreatment being tested

    Treatment: EB-1020 (Centanafadine) low dose

  • EB-1020(QD XR capsules) high doseTreatment being tested

    Treatment: EB-1020 (Centanafadine) high dose

  • PlaceboPlacebo, for comparison

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled, Japan-China Joint Trial to Evaluate the Efficacy and Safety of Two Dose Levels of EB-1020 QD XR Capsules Administered Orally Once Daily in Children and Adolescents With Attention-deficit/Hyperactivity Disorder
Fit questions
Built from NCT07086313, who can take part
Record updated
23 December 2025